

Docket No.: TDT-ADV-056(TJU0001-107)  
PATENT

Appl. Number: 10/621,684  
Filed: 07/17/03

### REMARKS

#### Status of the Claims

Claims 1-22 are in the application.

Claims 1-22 have been subject to a restriction requirement.

By way of this amendment, claims 1-22 have been canceled and new claims 23-44 have been added.

Upon entry of this amendment, claims 23-44 will be pending.

#### Summary of the Amendment

The claims have been amended to more specifically define aspects and embodiments of the invention. Support for the amendment is found throughout the specification such as on page 42-45. No new matter has been added.

#### Response to Restriction Requirement

Claims 1-22 have been made subject to a restriction requirement. In view of this preliminary amendment, Applicant elects for examination the invention defined by Group I, now claims 23-44. Applicant notes that the restriction requirement indicates that Group I refers to conjugated compositions. Applicants respectfully urge that the unconjugated compositions set forth in the newly added claims be included as the invention defined by Group I. Applicant believes that this response is fully responsive although unconjugated compositions are embraced by the new claims. If the Examiner concludes that Group I does not include unconjugated compositions and that conjugated compositions and unconjugated compositions are separate invention, Applicant respectfully requests that claims 23-44 be examined as directed to unconjugated compositions and conjugated compositions be withdrawn as a non-elected group.

Applicants elect SEQ ID NO:2 as the species of ST receptor binding ligand for initial examination.

Applicants elect 5-fluorouracil as the species of active agent for initial examination.

Each of claims 23-44 read on the elected species.

Docket No.: TDT-ADV-056(TJU0001-107)  
PATENT

Appl. Number: 10/621,684  
Filed: 07/17/03

### Conclusion

Claims 23-44 are in condition for allowance. An indication that the claims are in condition for allowance is earnestly solicited.

As indicated on the transmittal accompanying this response, the Commissioner is hereby authorized to charge any debit or credit any overpayment to Deposit Account No. 50-1275.

Respectfully submitted,



Mark DeLuca  
Registration No. 33,229

Date: February 1, 2005  
COZEN O'CONNOR, P.C.  
1900 Market Street  
Philadelphia, PA 19103-3508  
Telephone: 215.665.5592  
Facsimile: 215.665.2013

2192194v1